Strategic partnerships Leverage Gensaic’s collaboration history with Novo Nordisk to position joint development opportunities, co-innovation agreements, and expanded tissue-targeting programs for cardiometabolic diseases and age-related conditions.

AI-driven discovery Offer AI-first protein design and unbiased directed evolution services to accelerate partner programs, emphasizing FORGE technology as a differentiator for tissue-selective delivery of payloads such as RNA therapies.

Clinical and preclinical focus Target biotech and pharma groups seeking novel delivery modalities for gene therapies and RNA payloads, highlighting existing engagement with cystic fibrosis and CNS/CNS-related initiatives as evidence of broad tissue targeting capabilities.

Funding signals Capitalize on substantial disclosed funding rounds and high-profile collaborations to attract co-development capital, licensing deals, and milestone-driven partnerships with large biopharma players.

Infrastructure leverage Position Gensaic’s cloud and data-enabled workflow as enabling scalable programs for multiple targets, offering partner-specific implementation plans using their tech stack and cloud-based collaboration for rapid iteration.